Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice

Cancer Research

Volumn 57, Issue 14, 1997, Pages 2937-2942

  Iwanuma, Yoshimi ^a   Chen, Fang An ^a   Egilmez, Nejat K ^a   Takita, Hiroshi ^a   Bankert, Richard B ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; CD8 ANTIGEN; CYTOKINE; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 12;

ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL MONITORING; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; ETIOLOGY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR REJECTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; INTERLEUKIN-12; INTERLEUKIN-15; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTES; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030740303     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Reddy, S., Piccione, D., Takita, H., and Bankert, R. B. Human lung tumor growth established in the lung an subcutaneous tissue of mice with severe combined immunodeficiency. Cancer Res., 47: 2456-2460, 1987.
2. Mosier, D. E., Gulizia, R. J., Baird, S. M., and Wilson, D. B. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature (Lond.), 335: 256-259, 1988.
3. Tary-Lehmann, M., Lehmann, P. V., Schols, D., Roncarolo, M. G., and Saxon, A. Anti-SCID mouse reactivity shapes the human CD4+ T cell repertoire in hu-PBL-SCID chimeras. J. Exp. Med., 180: 1817-1827, 1994.
4. Tary-Lehmann, M., and Saxon, A. Human mature T cells that are anergic in vivo prevail in SCID mice reconstituted with human peripheral blood. J. Exp. Med., 175: 503-516, 1992.
5. Williams, S. S., Umemoto, T., Kida, H., Repasky, E. A., and Bankert, R. B. Engraftment of human peripheral blood leukocytes into severe combined immunodeficient mice results in the long term and dynamic production of human xenoreactivc antibodies. J. Immunol., 149: 2830-2836, 1992.
6. Williams, S. S., Chen, F-A., Kida, H., Yokota, S., Miya, K., Kato, M., Barcos, M. P., Wang, H-Q., Alosco, T., Umemoto, T., Croy, B. A., Repasky, E. A., and Bankert, R. B. Engraftment of human tumor-infiltrating lymphocytes and the production of anti-tumor antibodies in SCID mice. J. Immunol., 156: 1908-1915, 1996.
7. Whiteside, T. L., and Parmiani, G. Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use. Cancer Immunol. Immunother., 39: 15-21, 1994.
8. 1 integrin expression. Cell Adhes. Commun., 2: 345-357, 1994.
9. Katre, N. V., Knauf, M. J., and Laird, W. J. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc. Natl. Acad. Sci. USA, 84: 1487-1491, 1987.
10. Knauf, M. J., Bell, D. P., Hirtzer, P., Luo, Z-P., Young, J. D., and Katre, N. V. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J. Biol. Chem., 261: 15064-15070, 1988.
11. Zimmerman, R. J., Aukerman, S. L., Young, J. D., Katre, N. V., and Winkelhake, J. L. Schedule dependency of the anti-tumor activity and toxicity of polyethylene glycol-modified interleukin-2 in murine tumor models. Cancer Res., 49: 6521-6528, 1989.
12. Katre, N. V. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J. Immunol., 144: 209-213, 1990.
13. Alosco, T., Croy, B. A., Gansbacher, B., Wang, H. Q., Rao, U., and Bankert, R. B. Anti-tumor response independent of functional B or T lymphocytes induced by the local and sustained release of interleukin-2 by the tumor cells. Cancer Immunol. Immunother., 36: 364-372, 1993.
14. Walker, W., and Gallagher, G. The development of a novel immunotherapy model of human ovarian cancer in human PBL-severe combined immunodelicient (SCID) mice. Clin. Exp. Immunol., 101: 494-501, 1995.
15. Murphy, W. J., Conlon, K. C., Sayers, T. J., Wiltrout, R. H., Back, T. C. Ortaldo, J. R., and Longo, D. L. Engraftment and activity of anti-CD3-activated human peripheral blood lymphocytes transferred into mice with severe combined immune deficiency. J. Immunol., 150: 3634-3642, 1993.
16. Murphy, W. J., Back, T. C., Conlon, K. C., Komschlies, K. L., Ortaldo, J. R., Sayers, T. J., Wiltrout, R. H., and Longo, D. L. Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts. J. Clin. Invest., 92, 1918-1924, 1993.
17. Bankert, R. B., Umemoto, T., Sugiyama, Y., Chen, F. A., Repasky, E. A., and Yokotam S. Human lung tumors, patients' peripheral blood lymphocytes and tumor infiltrating lymphocytes propagated in SCID mice. Curr. Top. Microbiol. Immunol., 152: 201-210, 1989.
18. Chen, F-A., Williams, S., Fanslow, W. C., and Bankert, R. B. Human antibody response in human peripheral blood leukocyte/severe combined immunodeficient chimeric model is dependent on B and T cell costimulation via CD40/CD40 ligand. J. Immunol., 155: 2833-2840, 1995.
19. Cesano, A., Visonneau, S., Ciocé, L., Clark, S. C., Rovera, G., and Santoli, D. Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach. J. Clin. Invest., 94: 1076-1084, 1994.
20. Sabzevari, H., and Reisfeld, R. A. Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases in SCID/hu mice. Cancer Res., 53: 4933-4937, 1993.
21. Hill, L. L., Perussia, B., McCue, P. A., and Korngold, R. Effect of human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency. Cancer Res., 54: 763-770, 1994.
22. Brunda, M. J. Interleukin-12. J. Leukocyte Biol., 55: 280-288, 1994.
23. Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein, K., and Caligiuri, M. A. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med., 180: 1395-1403, 1994.
24. Trinchieri, G., and Scott, P. The role of interleukin 12 in the immune response, disease and therapy. Immunol. Today, 15: 460-463, 1994.
25. Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J., and Lotze, M. T. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol., 153: 1697-1706, 1994.
26. Winn, H. J. Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts. J. Immunol., 84: 228-239, 1960.